NEW YORK , April 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that Lucid's President & Chief Operating Officer Shaun O'Neil will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on... Read More

Quarterly EsoGuard ® revenue increased 33 percent sequentially Expanding EsoGuard clinical validity and clinical utility data poised to drive medical policy coverage, including line of sight to Medicare coverage Conference call and webcast to be held tomorrow, March 26 th at 8:30 AM ET NEW YORK , March 25, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer... Read More

Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy Authors conclude that EsoGuard is a "powerful screening tool" for esophageal precancer and cancer NEW YORK , March 21, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical... Read More

Lucid and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia NEW YORK , March 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today... Read More

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , March 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, March 26, 2024 , at 8:30 AM ET . During the... Read More

NEW YORK , Feb. 16, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that it was notified by the World Trade Center Health Program ("WTCHP") that, due to a clerical error, the EsoGuard ® Esophageal DNA test was incorrectly... Read More

Contrasts EsoCheck's powerful cell collection capabilities to "cruder, decades-old" technologies during comments on patient access to medical technology innovation NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today... Read More

The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants NEW YORK , Feb. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that it has contracted with the World... Read More

PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock NEW YORK , Dec. 11, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors today provided additional details on the previously... Read More

Industry veterans join executive team as VP, Market Access and VP, Employer Markets Shaun M. O'Neil promoted to Lucid's President and COO NEW YORK , Nov. 16, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), announced that the Company has... Read More

Lucid's quarterly revenue increased 392 percent sequentially Veris Health commercial expansion efforts underway, with next-generation Veris Cancer Care Platform launching in Q4 Conference call and webcast to be held tomorrow, November 15 th at 8:30 AM EST NEW YORK , Nov. 14, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating... Read More

Quarterly EsoGuard ® test volume and revenue increased 17 percent and 392 percent sequentially, respectively Conference call and webcast to be held tomorrow, November 14 th at 8:30 AM EST NEW YORK , Nov. 13, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)... Read More

EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and lower costs Lucid Diagnostics Investor Day, where Lucid executives, key opinion leaders, and other experts will discuss Lucid's business and technologies, to be held in New York City on December 13 th NEW YORK , Nov. 9, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq:... Read More

Lishan Aklog , M.D., Chairman & CEO, to Present November 16, 2023 , in New York NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced its Chairman and Chief Executive Officer, Dr. Lishan Aklog , will present at the... Read More

Clinical registries are collecting real-world clinical utility and clinical validity data on EsoGuard testing in general at-risk populations and firefighters, respectively Initial combined analysis of clinical utility in 437 patients documents excellent concordance of EsoGuard results with subsequent medical decision-making and over 99 percent technical success NEW YORK , Oct. 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc.... Read More

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , Oct. 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, November 14, 2023 , at 8:30 AM EST . During... Read More

Multicenter observational study documents excellent concordance of EsoGuard results with subsequent medical decision-making by multiple physicians NEW YORK , Sept. 7, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced it has... Read More

EsoGuard Testing now incorporated in Texas -based Ancira Auto Group's corporate Health and Wellness Program NEW YORK , Aug. 24, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), announced that the Company has contracted with the Ancira Auto Group ("Ancira"),... Read More

EsoGuard ® test volume continues to grow as Lucid makes strides with commercial expansion and additional supporting data Veris Health prepares to launch the next generation of the Veris Cancer Care Platform along with strategic initiatives to develop a biopharma companion digital module to support new cancer therapeutics and to seek FDA clearance as a SaMD Conference call and webcast to be held tomorrow, August 16 th at 8:30... Read More

Quarterly EsoGuard ® test volume increased 20 percent sequentially and 159 percent annually Revenue cycle management upgrade completed with immediate positive impact to claims processing and payments Unprecedented cancer and precancer detection results from an NCI-funded EsoGuard study released Conference call and webcast to be held tomorrow, August 15 th at 8:30 AM EDT NEW YORK , Aug. 14, 2023 /PRNewswire/ -- Lucid... Read More

NEW YORK , July 26, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that Shaun O'Neil, Executive Vice President & Chief Operating Officer, will participate in a fireside chat at the Canaccord Genuity 43 rd Annual Growth Conference on... Read More

Advocated stronger transparency and predictability, and inclusion of diagnostics, in federal proposals to improve equitable access to innovative lifesaving technologies Highlighted EsoGuard's life-saving potential, and unprecedented early detection results of a recently posted NCI-supported EsoGuard study NEW YORK , July 19, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage... Read More

First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota, Florida NEW YORK , June 5, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced the launch... Read More

EsoGuard ® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint Conference call and webcast to be held tomorrow, May 17 th at 8:30 AM EST NEW YORK , May 16, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device,... Read More

EsoGuard ® test volume increases 57 percent sequentially and 245 percent year-on-year Conference call and webcast to be held tomorrow, May 16 th at 8:30 AM EST NEW YORK , May 15, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a... Read More

EsoGuard ® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic Barrett's Esophagus EsoCheck ® cell collection performed with 98 percent technical success and high DNA yields in real-world study of 1483 patients NEW YORK , May 11, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid"... Read More

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , May 5, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, May 16, 2023 , at 8:30 AM EST . During the... Read More

Lucid's CLIA laboratory, which performs its EsoGuard test, operates within Noridian's jurisdiction Noridian's foundational LCD, to become effective May 28, 2023 , closely aligns with the LCD recently published by the MolDx Program Lucid remains focused on securing clinical utility data and submitting EsoGuard for Technical Assessment and coverage under these foundational LCDs later this year NEW YORK , April 18, 2023... Read More

Foundational LCD, to be effective May 14, 2023 , incorporates key feedback to 2022 draft, including updated guidelines recommending non-endoscopic biomarker testing Lucid positioned to submit EsoGuard for Technical Assessment and coverage under foundational LCD when sufficient clinical utility data available later this year NEW YORK , March 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics"... Read More

Conference call and webcast to be held tomorrow, March 15 th at 8:30 AM EST NEW YORK , March 14, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD)... Read More

4Q22 and projected 1Q23 EsoGuard ® test volume increases 8 and 36 percent sequentially and 288 and 300 percent annually. Company signs in-network agreement with largest secondary PPO, MultiPlan, expanding patient access to EsoGuard. Company secures financing of $24.6 million through separate offerings of preferred stock and debt, convertible after September 2023 . Conference call and webcast to be held tomorrow, March 14 th... Read More

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , March 3, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, March 14, 2023 , at 8:30 AM EST . During the... Read More

Partners with San Antonio Fire Department to test nearly 400 firefighters for esophageal precancer during Firefighter Cancer Awareness Month over two weekends, averaging nearly 100 tests per day Expands utilization of satellite Lucid Test Centers in support of National Cancer Prevention Month NEW YORK , Feb. 15, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage... Read More